C81.08
Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of multiple sites
Clinical Classification Guidelines
Medical Intelligence & Overview
Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is a rare type of Hodgkin lymphoma characterized by the growth of abnormal lymphocytes called lymphocytes. Specifically, this form involves multiple lymph nodes across different parts of the body. Recognized under ICD-10 code C81.08, it is important to understand its nature, causes, symptoms, and general approaches to diagnosis and management.
Causes & Symptoms
Clinical Causes: Genetic factors influencing immune system regulation Potential exposure to certain viruses, such as Epstein-Barr virus (EBV), though not directly proven as a cause Environmental factors that are still being studied, with no conclusive evidence linking specific exposures
Key Symptoms: Swelling or painless lumps in lymph nodes, often in the neck, armpits, or groin Persistent fatigue and weakness Unexplained weight loss Fever that comes and goes Night sweats Itching all over the body General feeling of discomfort or malaise
Diagnostic & Treatment
Diagnosis Path: Physical exam to check for swollen lymph nodes and related symptoms Imaging tests such as PET scans or CT scans to identify affected lymph node regions Lymph node biopsy to examine tissue microscopically, confirming the presence of characteristic lymphocyte patterns of NLPHL Blood tests to assess overall health and rule out other conditions
Treatment Protocols: Radiation therapy targeted at affected lymph nodes Chemotherapy regimens tailored to individual cases Monitoring and watchful waiting in certain early or indolent cases Emerging targeted therapies and immunotherapies in clinical trials Supportive care to manage symptoms and maintain quality of life
Clinical Advice & FAQs
Billing Guidance
Is C81.08 a billable ICD-10 code?
Yes, C81.08 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report C81.08?
Clinical documentation must specify the nature of Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of multiple sites and any associated comorbidities for accurate reporting.
Cite this Clinical Reference